We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4
Read MoreHide Full Article
NextGen Healthcare, Inc. reported fourth-quarter fiscal 2020 adjusted earnings per share (EPS) of 20 cents, beating the Zacks Consensus Estimate of 19 cents by 5.3%. However, the bottom line declined 13% from the prior-year quarter.
For fiscal 2020, adjusted EPS came in at 83 cents, down 3.5% from the previous period. The metric outpaced the Zacks Consensus Estimate of 81 cents.
Revenue Details
Revenues of this Zacks Rank #3 (Hold) company amounted to $136.4 million, up 1.2% year over year. Moreover, the top line surpassed the Zacks Consensus Estimate by 0.4%.
For fiscal 2020, revenues grossed $540.2 million, up 2.1% from the prior-year period. However, the metric missed the consensus mark by 0.1%.
NEXTGEN HEALTHCARE, INC Price, Consensus and EPS Surprise
Bookings for the quarter came in at $31 million, down 12.4% from the year-ago quarter.
Segment Details
The company reported fourth-quarter fiscal 2020 revenues under the following segments:
Total Recurring revenues were $124.5 million, up 3.6% from the year-ago quarter.
Meanwhile, total Software, hardware and other non-recurring revenues amounted to $11.9 million, down 18.7% on a year-over-year basis.
Margin
In the quarter under review, gross profit totaled $68 million, down 6.4% from the prior-year quarter. Gross margin was 49.9%, down 400 basis points (bps).
Operating loss in the fiscal fourth quarter was $6.3 million, against the year-ago quarter’s operating income of $6.5 million.
Fiscal 2021 Guidance
NextGen announced in its business update on Apr 28, 2020 that it will not issue any guidance for fiscal 2021 or the years beyond considering the uncertainty surrounding the COVID-19 pandemic. The company will decide on guidance after evaluating the scenario once it stabilizes and there is more confidence in the macro environment.
Summing Up
NextGen exited the fiscal fourth quarter on a strong note. The company benefited from its Recurring segment in the quarter under review. Meanwhile, NextGen’s Software, hardware and other non-recurring revenues were soft in the quarter under review. Bookings also declined in the quarter. Significant contraction in gross margin remains a concern. Additionally, NextGen faces stiff rivalry in the MedTech space.
Key Picks
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, beating the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million surpassed the consensus mark by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly reported first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade. See the 5 high-tech stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4
NextGen Healthcare, Inc. reported fourth-quarter fiscal 2020 adjusted earnings per share (EPS) of 20 cents, beating the Zacks Consensus Estimate of 19 cents by 5.3%. However, the bottom line declined 13% from the prior-year quarter.
For fiscal 2020, adjusted EPS came in at 83 cents, down 3.5% from the previous period. The metric outpaced the Zacks Consensus Estimate of 81 cents.
Revenue Details
Revenues of this Zacks Rank #3 (Hold) company amounted to $136.4 million, up 1.2% year over year. Moreover, the top line surpassed the Zacks Consensus Estimate by 0.4%.
For fiscal 2020, revenues grossed $540.2 million, up 2.1% from the prior-year period. However, the metric missed the consensus mark by 0.1%.
NEXTGEN HEALTHCARE, INC Price, Consensus and EPS Surprise
NEXTGEN HEALTHCARE, INC price-consensus-eps-surprise-chart | NEXTGEN HEALTHCARE, INC Quote
Bookings Update
Bookings for the quarter came in at $31 million, down 12.4% from the year-ago quarter.
Segment Details
The company reported fourth-quarter fiscal 2020 revenues under the following segments:
Total Recurring revenues were $124.5 million, up 3.6% from the year-ago quarter.
Meanwhile, total Software, hardware and other non-recurring revenues amounted to $11.9 million, down 18.7% on a year-over-year basis.
Margin
In the quarter under review, gross profit totaled $68 million, down 6.4% from the prior-year quarter. Gross margin was 49.9%, down 400 basis points (bps).
Operating loss in the fiscal fourth quarter was $6.3 million, against the year-ago quarter’s operating income of $6.5 million.
Fiscal 2021 Guidance
NextGen announced in its business update on Apr 28, 2020 that it will not issue any guidance for fiscal 2021 or the years beyond considering the uncertainty surrounding the COVID-19 pandemic. The company will decide on guidance after evaluating the scenario once it stabilizes and there is more confidence in the macro environment.
Summing Up
NextGen exited the fiscal fourth quarter on a strong note. The company benefited from its Recurring segment in the quarter under review. Meanwhile, NextGen’s Software, hardware and other non-recurring revenues were soft in the quarter under review. Bookings also declined in the quarter. Significant contraction in gross margin remains a concern. Additionally, NextGen faces stiff rivalry in the MedTech space.
Key Picks
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, beating the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million surpassed the consensus mark by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly reported first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
See the 5 high-tech stocks now>>